778 related articles for article (PubMed ID: 27404381)
21. Deregulated microRNAs in triple-negative breast cancer revealed by deep sequencing.
Chang YY; Kuo WH; Hung JH; Lee CY; Lee YH; Chang YC; Lin WC; Shen CY; Huang CS; Hsieh FJ; Lai LC; Tsai MH; Chang KJ; Chuang EY
Mol Cancer; 2015 Feb; 14():36. PubMed ID: 25888956
[TBL] [Abstract][Full Text] [Related]
22. MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer.
Xu X; Zhang Y; Jasper J; Lykken E; Alexander PB; Markowitz GJ; McDonnell DP; Li QJ; Wang XF
Oncotarget; 2016 Apr; 7(15):20381-94. PubMed ID: 26967387
[TBL] [Abstract][Full Text] [Related]
23. Low Expression of Circulating MicroRNA-34c is Associated with Poor Prognosis in Triple-Negative Breast Cancer.
Zeng Z; Chen X; Zhu D; Luo Z; Yang M
Yonsei Med J; 2017 Jul; 58(4):697-702. PubMed ID: 28540980
[TBL] [Abstract][Full Text] [Related]
24. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients.
Eichelser C; Stückrath I; Müller V; Milde-Langosch K; Wikman H; Pantel K; Schwarzenbach H
Oncotarget; 2014 Oct; 5(20):9650-63. PubMed ID: 25333260
[TBL] [Abstract][Full Text] [Related]
25. miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer.
Chen J; Shin VY; Siu MT; Ho JC; Cheuk I; Kwong A
BMC Cancer; 2016 Nov; 16(1):887. PubMed ID: 27842518
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
[TBL] [Abstract][Full Text] [Related]
27. Identification of dysregulated microRNAs in triple-negative breast cancer (review).
Yang F; Zhang W; Shen Y; Guan X
Int J Oncol; 2015 Mar; 46(3):927-32. PubMed ID: 25571912
[TBL] [Abstract][Full Text] [Related]
28. Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration.
Terkelsen T; Russo F; Gromov P; Haakensen VD; Brunak S; Gromova I; Krogh A; Papaleo E
Breast Cancer Res; 2020 Jun; 22(1):73. PubMed ID: 32605588
[TBL] [Abstract][Full Text] [Related]
29. Aberrant miRNAs expressed in HER-2 negative breast cancers patient.
Braicu C; Raduly L; Morar-Bolba G; Cojocneanu R; Jurj A; Pop LA; Pileczki V; Ciocan C; Moldovan A; Irimie A; Eniu A; Achimas-Cadariu P; Paradiso A; Berindan-Neagoe I
J Exp Clin Cancer Res; 2018 Oct; 37(1):257. PubMed ID: 30342533
[TBL] [Abstract][Full Text] [Related]
30. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.
Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ
Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649
[TBL] [Abstract][Full Text] [Related]
31. Expression of miRNAs Targeting mTOR and S6K1 Genes of mTOR Signaling Pathway Including miR-96, miR-557, and miR-3182 in Triple-Negative Breast Cancer.
Razaviyan J; Hadavi R; Tavakoli R; Kamani F; Paknejad M; Mohammadi-Yeganeh S
Appl Biochem Biotechnol; 2018 Dec; 186(4):1074-1089. PubMed ID: 29862445
[TBL] [Abstract][Full Text] [Related]
32. Novel genes associated with lymph node metastasis in triple negative breast cancer.
Mathe A; Wong-Brown M; Morten B; Forbes JF; Braye SG; Avery-Kiejda KA; Scott RJ
Sci Rep; 2015 Nov; 5():15832. PubMed ID: 26537449
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-155, induced by FOXP3 through transcriptional repression of BRCA1, is associated with tumor initiation in human breast cancer.
Gao S; Wang Y; Wang M; Li Z; Zhao Z; Wang RX; Wu R; Yuan Z; Cui R; Jiao K; Wang L; Ouyang L; Liu R
Oncotarget; 2017 Jun; 8(25):41451-41464. PubMed ID: 28562349
[TBL] [Abstract][Full Text] [Related]
34. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer.
Hu J; Xu J; Wu Y; Chen Q; Zheng W; Lu X; Zhou C; Jiao D
Tumour Biol; 2015 Jan; 36(1):251-8. PubMed ID: 25238878
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
36. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
37. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
38. miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer.
Son D; Kim Y; Lim S; Kang HG; Kim DH; Park JW; Cheong W; Kong HK; Han W; Park WY; Chun KH; Park JH
Cancer Lett; 2019 Jul; 454():224-233. PubMed ID: 31004703
[TBL] [Abstract][Full Text] [Related]
39. miR-135b promotes proliferation and metastasis by targeting APC in triple-negative breast cancer.
Lv ZD; Xin HN; Yang ZC; Wang WJ; Dong JJ; Jin LY; Li FN
J Cell Physiol; 2019 Jul; 234(7):10819-10826. PubMed ID: 30624764
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
